Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
about
Genetics of endometrial cancersInfrequent methylation of the DUSP6 phosphatase in endometrial cancer.Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancerHuman breast tumor cells are more resistant to cardiac glycoside toxicity than non-tumorigenic breast cells.Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers.ERK/pERK expression and B-raf mutations in colon adenocarcinomas: correlation with clinicopathological characteristics.The genomics and genetics of endometrial cancer.MEK inhibition suppresses cell invasion and migration in ovarian cancers with activation of ERK1/2.Activation of MEK1/2-ERK1/2 signaling during NNK-induced lung carcinogenesis in female A/J mice.A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group studyCandidate biomarkers for genetic and clinicopathological diagnosis of endometrial cancerKRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancerKRAS and MAPK1 gene amplification in type II ovarian carcinomas.Glycogen synthase kinase 3β inhibition as a therapeutic approach in the treatment of endometrial cancer.Inhibition of nuclear factor-kappa B enhances the tumor growth of ovarian cancer cell line derived from a low-grade papillary serous carcinoma in p53-independent pathwayEndometrial tumour BRAF mutations and MLH1 promoter methylation as predictors of germline mismatch repair gene mutation status: a literature review.Complex interactions between the components of the PI3K/AKT/mTOR pathway, and with components of MAPK, JAK/STAT and Notch-1 pathways, indicate their involvement in meningioma development.Gene status of head and neck squamous cell carcinoma cell lines and cetuximab-mediated biological activities.Tyr phosphatase-mediated P-ERK inhibition suppresses senescence in EIA + v-raf transformed cells, which, paradoxically, are apoptosis-protected in a MEK-dependent mannerEpisodic Src activation in uveal melanoma revealed by kinase activity profiling.Loss of integrin alpha1beta1 ameliorates Kras-induced lung cancer.ERK phosphorylation is not increased in papillary thyroid carcinomas with BRAF(V600E) mutation compared to that of corresponding normal thyroid tissues.The expression of ER, PR in endometrial cancer and analysis of their correlation with ERK signaling pathway.Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.Expression of pERK and pAKT in human astrocytomas: correlation with IDH1-R132H presence, vascular endothelial growth factor, microvascular characteristics and clinical outcome.
P2860
Q33781274-40FFB0CC-81C4-4F83-8CF7-5FC6AFA49391Q34127155-FCDEB433-186C-49E4-8FD2-C8EC178535F3Q34253654-4A85B363-8C6F-44D5-B7E0-53CAEF1E4FA1Q35071149-9B32D88E-0BE6-4774-8197-165E34212324Q35623021-34AD8732-CB86-41A0-ABED-50ED564EBEB3Q35873526-F42C0D1B-B536-4219-ADA4-7874D4FED7F4Q36151896-06C8CD6D-8ADE-487E-BC70-7628D863AFFCQ36244064-20D30B53-ACA3-413B-AF72-81C128B2504FQ36895110-33C6598B-8C50-4804-B011-38672816D3F8Q36980484-24D842DA-F129-40AA-BC3F-3BEA51161364Q37007297-1A6F46A4-AB88-4106-B213-A047E30DD95AQ37023905-A5E7A99A-D014-493D-816E-AB1E48C3283DQ37091859-134B889E-ADD2-424D-AC5A-1627D1DEC88BQ37139199-DA63F133-9840-40FE-9C36-BFFFEE00B978Q37148431-D110D13F-0396-4B0B-8DD5-D6C7A6A4A5F1Q38123671-27658833-420F-4734-902A-6F9CFF306C1DQ38963912-56DEAAFC-6DEF-4761-B738-5D7320918D74Q39532332-8C8F4A1C-27C9-4627-8ED3-27C88841E0FDQ39576124-8E5D6789-38BA-4167-A919-B79AA3D13712Q39830805-42B35495-08B4-4D95-99CD-CAE62B0EF8FFQ41884394-5BAF6B60-9A44-482F-AD2D-4F0FEB8D3B84Q46343415-37C70780-8D54-43A2-9B63-6849A6A1B934Q47590366-3E305BA9-3814-466D-AC12-A21955028C8AQ51150179-62CA4AE0-DF10-4FBD-9BFA-3AFF926C2900Q53227600-DE9CB5D1-391A-49B0-924D-1D63ED016C46Q55463212-6B91C98F-6BA0-4E9C-AA89-F27997EF95E1
P2860
Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Activation of ERK1/2 occurs in ...... ated with favorable prognosis.
@en
type
label
Activation of ERK1/2 occurs in ...... ated with favorable prognosis.
@en
prefLabel
Activation of ERK1/2 occurs in ...... ated with favorable prognosis.
@en
P2093
P2860
P1433
P1476
Activation of ERK1/2 occurs in ...... ated with favorable prognosis.
@en
P2093
Junko Sakaguchi
Manabu Hashimoto
Masahiro Takakura
Masaki Inoue
Noriko Mori
Satoru Kyo
Satoshi Ohno
Yasunari Mizumoto
Yoshiko Maida
P2860
P304
P356
10.1111/J.1349-7006.2007.00445.X
P577
2007-03-27T00:00:00Z